Asked Gemini AI -
When might the first aging reversal genetic drug therapies for far-sightedness (to reverse needing reading glasses) become available, FDA approved?
https://g.co/gemini/share/9b41ff642f37
"It's important to clarify the distinction between "aging reversal genetic drug therapies" and current presbyopia treatments.
-
Presbyopia treatments currently available or in late-stage development are primarily eye drops that use a "pinhole effect" or similar mechanisms to temporarily improve near vision.
These drops, like Vuity (approved 2021) and Qlosi (approved 2023), work by constricting the pupil, which increases the depth of focus. They don't reverse the underlying aging process of the lens that causes presbyopia, but rather manage the symptoms. Several other such drops are in the pipeline, with some expected to launch in 2025 or early 2026 (e.g., LNZ100 by LENZ Therapeutics has an FDA target action date of August 8, 2025; BRIMOCHOL PF by Tenpoint Therapeutics hopes to launch in the first half of 2026). -
"Aging reversal genetic drug therapies" for presbyopia would be a much more significant breakthrough. These would aim to restore the natural flexibility of the eye's lens, which hardens with age and causes presbyopia. This is a far more complex challenge.
While there's active research into anti-aging therapies, including those that might target age-related eye conditions, truly "aging reversal genetic drug therapies" for presbyopia are still in the much earlier stages of research and development.
Here's why you won't find a near-term FDA approval date for such a therapy:
- Complexity of reversing aging: Reversing cellular or molecular aging processes is a monumental scientific challenge, and we're still in the early phases of understanding and manipulating these fundamental biological pathways.
- Targeting the crystalline lens: Presbyopia is caused by the stiffening of the eye's natural lens.
A genetic therapy would likely need to either: - Induce the lens cells to produce proteins that restore flexibility.
- Target the mechanisms that cause protein cross-linking and stiffening in the first place.
- Replace aged lens cells with new, functional ones (a form of regenerative medicine).
- Long clinical trial process: Even if a promising candidate emerges, genetic therapies undergo rigorous and lengthy clinical trials (Phase 1, 2, 3) to prove safety and efficacy. This process alone can take many years, often a decade or more, before an FDA application is even submitted.
Therefore, while the current "presbyopia drops" are becoming more widely available, truly aging-reversal genetic drug therapies to reverse the need for reading glasses are likely many years, if not decades, away from FDA approval. These would represent a fundamental shift in treating age-related conditions, and we are not yet at that stage for presbyopia."
https://g.co/gemini/share/9b41ff642f37
* * *
Is Spencer Wells' 2002 fwd "out of Africa" theory discredited by Brook Larmer's 2025 "The Hunt for the Other Humans" 2025 "National Geographic" article?
Is @spwells' (2002 fwd) "#OutOfAfrica" theory discredited by @brooklarmer's 2025 "#TheHuntForTheOtherHumans" in a "#NationalGeographic" article? #GeminiAI says supplements: https://g.co/gemini/share/
AAAB
https://x.com/WorldUnivAndSch/
https://x.com/WUaSPress/
https://x.com/TheOpenBand/
https://x.com/HarbinBook/
https://x.com/scottmacleod/
https://x.com/Q_YogaMacFlower/
https://x.com/sgkmacleod/
SF Bay Area: wiki.
Larmer, Brook. 2025. The Hunt for the Other Humans. February, Vol. 247, No. 2. Washington DC: National Geographic.
https://www.
October 24, 2014
https://www.npr.org/2014/10/
28 Oct 2010
--
*
https://en.wikipedia.org/wiki/Tarsier
https://commons.wikimedia.org/wiki/Tarsius
https://commons.wikimedia.org/wiki/Category:Tarsius_tarsier
https://species.wikimedia.org/wiki/Tarsiidae
...
Posts
No comments:
Post a Comment